Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 13/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569651 | 0.83 | CXCR2 (0.47) | CXCR2CXCR1 | |
| SCHEMBL1487129 | 0.83 | CXCR2 (0.47) | CXCR2CXCR1 | |
| SCHEMBL1487135 | 0.83 | CXCR2 (0.47) | CXCR2CXCR1 | |
| SCHEMBL1487182 | 0.72 | CXCR2 (0.64) | CXCR2CXCR1 | |
| SCHEMBL1487377 | 0.70 | CXCR2 (0.49) | CXCR2CXCR1 | |
| SCHEMBL1487098 | 0.69 | CXCR2 (0.54) | CXCR2CXCR1 | |
| SCHEMBL5569979 | 0.69 | CXCR2 (0.54) | CXCR2CXCR1 | |
| SCHEMBL1487190 | 0.69 | CXCR2 (0.54) | CXCR2CXCR1 | |
| SCHEMBL1487027 | 0.69 | CXCR2 (0.56) | CXCR2CXCR1 | |
| SCHEMBL4229659 | 0.69 | CXCR2 (0.61) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885PKM 1956/4885CXCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.